Interferon-alpha 2b (IFN-α2b) and Ribavirin are two licensed antiviral drugs that protects monkeys from MERS virus, as reported by a research team from the National Institute of Allergy and Infectious Diseases, in cooperation with Canadian and French scientists.
The study, published in the September 8 edition of Nature Medicine, confirmed previous experiments that led to hypothesize that a combination of these two antivirals, routinely used together to treat viral diseases such as hepatitis C, could be effective against the novel β coronavirus that, so far, has caused 108 human cases of